Evidence map›Paper›PMID 35019857›Full record

ArticleBlood cancer discovery2022

Rare Sequences Make Sense of CAR T-cell Therapy Outcomes.

Sara Ghorashian, Jack Bartram

Abstract readComment
In one paragraph

Article in Blood cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sara GhorashianDepartment of Haematology Great Ormond Street Hospital for Children, London, United Kingdom. s.ghorashian@ucl.ac.uk.ORCID 0000-0002-1555-2946
Jack BartramDepartment of Haematology Great Ormond Street Hospital for Children, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue, Pulsipher and colleagues used next-generation sequencing to detect leukemia-specific sequences following tisagenlecleucel therapy of acute lymphoblastic leukemia. A challenge for the field currently is to identify which patients will have therapy failure and to do so early enough to allow planning for further treatment, for example, stem cell transplantation. Detection of disease below the standard detection level for this technique (less than one per million cells) at day 28 was associated with poorer outcomes and potentially therefore could be used to identify those that might benefit from adjunctive therapies.

Indexed as

Immunotherapy, AdoptivePrecursor Cell Lymphoblastic Leukemia-LymphomaChildHigh-Throughput Nucleotide SequencingHumansNeoplasm, ResidualReceptors, Antigen, T-CellRecurrenceYoung AdultReceptors, Antigen, T-Celltisagenlecleucel

Identifiers

PMID35019857
PMCPMC9783948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.